Research Article

Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule

https://orcid.org/0000-0003-3281-6517

Department of Medicine, College of Medicine, University of Illinois at Chicago, IL 60612, USA

Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, IL 60612, USA

Search for more papers by this author

Arivarasu N Anbazhagan

https://orcid.org/0000-0002-0231-9272

Department of Medicine, College of Medicine, University of Illinois at Chicago, IL 60612, USA

Search for more papers by this author

Shubha Priyamvada

https://orcid.org/0000-0002-7241-569X

Department of Medicine, College of Medicine, University of Illinois at Chicago, IL 60612, USA

Search for more papers by this author

Anoop Kumar

https://orcid.org/0000-0001-7915-3365

Department of Medicine, College of Medicine, University of Illinois at Chicago, IL 60612, USA

Jesse Brown VA Medical Center, Chicago, IL 60612, USA

Search for more papers by this author

Seema Saksena

https://orcid.org/0000-0002-2166-6317

Department of Medicine, College of Medicine, University of Illinois at Chicago, IL 60612, USA

Jesse Brown VA Medical Center, Chicago, IL 60612, USA

Search for more papers by this author

Hayat Onyuksel

https://orcid.org/0000-0002-2693-4069

Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, IL 60612, USA

Search for more papers by this author

Pradeep K Dudeja

*Author for correspondence: Tel.: +1 (312) 569 7434;

E-mail Address: pkdudeja@uic.edu

https://orcid.org/0000-0003-2252-7703

Department of Medicine, College of Medicine, University of Illinois at Chicago, IL 60612, USA

Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, IL 60612, USA

Jesse Brown VA Medical Center, Chicago, IL 60612, USA

Search for more papers by this author

Published Online:25 Sep 2020https://doi.org/10.2217/nnm-2020-0280

View article

Abstract

Aim: To evaluate the efficacy of locally delivered nanomedicine, vasoactive intestinal peptide in sterically stabilized micelles (VIP-SSM) to the colon and conduct in vitro release studies of a potential oral formulation. Materials & methods: Intracolonic instillation of VIP-SSM was tested in a mouse model of dextran sulfate sodium-induced colitis. Based on the effective mouse dose, human equivalent dose containing nanomedicine powder was filled into enteric coated capsules for in vitro release testing. Results: Colonic delivery of VIP-SSM significantly alleviated colitis. VIP-SSM containing capsules completely dissolved at colonic pH allowing micelles to reform with active VIP. Capsule formulations exhibited reproducible release profiles when stored up to 6 weeks demonstrating stability. Conclusion: VIP-SSM is an effective nanomedicine formulation which appears to have potential for oral treatment of colitis in humans.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Abad C, Waschek JA. Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. Curr. Pharm. Des. 17(10), 1025–1035 (2011).
Medline CASGoogle Scholar
2. Delgado M, Martinez C, Pozo D et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol. 162(2), 1200–1205 (1999).
Medline CASGoogle Scholar
3. Gomariz R, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des. 7(2), 89–111 (2001).
Medline CASGoogle Scholar
4. Smalley S, Barrow P, Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin. Exp. Immunol. 157(2), 225–234 (2009). • Highlights the immunomodulatory properties of vasoactive intestinal peptide (VIP) and therefore forms the basis of its use in inflammatory diseases.
Medline CASGoogle Scholar
5. Seo S, Miyake H, Alganabi M et al. Vasoactive intestinal peptide decreases inflammation and tight junction disruption in experimental necrotizing enterocolitis. J. Pediatr. Surg. 54(12), 2520–2523 (2019).
MedlineGoogle Scholar
6. Campbell J, Berry J, Liang Y. Anatomy and physiology of the small intestine. In: Shackelford's Surgery of the Alimentary Tract - 2 Volume Set. Elsevier, PA, USA, 817–841 (2019).
Google Scholar
7. Seillet C, Luong K, Tellier J et al. The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity. Nat. Immunol. 21, 168–177 (2019).
MedlineGoogle Scholar
8. Jönsson M, Norrgård Ö, Hansson M, Forsgren S. Decrease in binding for the neuropeptide VIP in response to marked inflammation of the mucosa in ulcerative colitis. Ann. NY Acad. Sci. 1107(1), 280–289 (2007).
MedlineGoogle Scholar
9. Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am. J. Gastroenterol. 87(2), 176–181 (1992).
Medline CASGoogle Scholar
10. Cassuto J, Fahrenkrug J, Jodal M, Tuttle R, Lundgren O. Release of vasoactive intestinal polypeptide from the cat small intestine exposed to cholera toxin. Gut 22(11), 958–963 (1981).
Medline CASGoogle Scholar
11. Guan X, Karpen HE, Stephens J et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130(1), 150–164 (2006).
Medline CASGoogle Scholar
12. Dharmsathaphorn K, Harms V, Yamashiro DJ, Hughes R, Binder H, Wright E. Preferential binding of vasoactive intestinal polypeptide to basolateral membrane of rat and rabbit enterocytes. J. Clin. Invest. 71(1), 27–35 (1983).
Medline CASGoogle Scholar
13. Jayawardena D, Guzman G, Gill RK, Alrefai WA, Onyuksel H, Dudeja PK. Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 313(1), G16–G25 (2017). • The presence of VPAC1 receptors in human and mouse colonic epithelium is characterized. This is the receptor which we target in this manuscript.
MedlineGoogle Scholar
14. Jayawardena D, Anbazhagan AN, Guzman G, Dudeja PK, Onyuksel H. Vasoactive intestinal peptide nanomedicine for the management of inflammatory bowel disease. Mol. Pharm. 14(11), 3698–3708 (2017). •• This is the first time vasoactive intestinal peptide in sterically stabilized micelles (VIP-SSM) was tested in colitis and the optimal dose for the current study was decided upon.
Medline CASGoogle Scholar
15. Abad C, Martinez C, Juarranz MG et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124(4), 961–971 (2003). • Describes the beneficial effect of VIP for the first time in Inflammatory bowel disease. Frequent high doses were used for alleviating inflammation.
Medline CASGoogle Scholar
16. Motlekar NA, Youan B-BC. The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins. J. Control. Rel. 113(2), 91–101 (2006).
Medline CASGoogle Scholar
17. Lim SB, Rubinstein I, Önyüksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles. Int. J. Pharm. 356(1–2), 345–350 (2008). • VIP-SSM freeze dried product is characterized, thereby demonstrating the stability of this peptide nanomedicine during the freeze drying process.
Medline CASGoogle Scholar
18. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7(2), 27 (2016). • Interspecies dosage conversion is discussed which was employed in the calculation of the human equivalent dose.
MedlineGoogle Scholar
19. Sethi V, Rubinstein I, Kuzmis A, Kastrissios H, Artwohl J, Onyuksel H. Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. Mol. Pharm. 10(2), 728–738 (2013). •• VIP-SSM nanomedicine was characterized for its physico-chemical properties and demonstrated the stability of this formulation in vivo.
Medline CASGoogle Scholar
20. Banerjee A, Onyuksel H. Peptide delivery using phospholipid micelles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4(5), 562–574 (2012).
Medline CASGoogle Scholar
21. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Rel. 163(1), 34–45 (2012).
Medline CASGoogle Scholar
22. Vukovic L, Madriaga A, Kuzmis A et al. Solubilization of therapeutic agents in micellar nanomedicines. Langmuir 29(51), 15747–15754 (2013). • VIP-SSM structure was determined by molecular dynamic simulation studies.
Medline CASGoogle Scholar
23. Krawisz J, Sharon P, Stenson W. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: assessment of inflammation in rat and hamster models. Gastroenterology 87(6), 1344–1350 (1984).
Medline CASGoogle Scholar
24. Viennois E, Chen F, Laroui H, Baker MT, Merlin D. Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA. BMC Res. Notes 6(1), 360 (2013).
MedlineGoogle Scholar
25. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3(6), 1101–1108 (2008).
Medline CASGoogle Scholar
26. Lindén SK, Florin TH, Mcguckin MA. Mucin dynamics in intestinal bacterial infection. PLoS ONE 3(12), e3952 (2008).
MedlineGoogle Scholar
27. McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm. 364(2), 213–226 (2008).
Medline CASGoogle Scholar
28. Önyüksel H, Bodalia B, Sethi V, Dagar S, Rubinsteina I. Surface-active properties of vasoactive intestinal peptide*. Peptides 21(3), 419–423 (2000).
MedlineGoogle Scholar
29. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12(12), 720–727 (2015).
MedlineGoogle Scholar
30. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4(4), 298 (2005).
Medline CASGoogle Scholar
31. Lewis AL, Richard J. Challenges in the delivery of peptide drugs: an industry perspective. Ther. Deliv. 6(2), 149–163 (2015).
Medline CASGoogle Scholar
32. Richard J. Challenges in oral peptide delivery: lessons learnt from the clinic and future prospects. Ther. Deliv. 8(8), 663–684 (2017).
Medline CASGoogle Scholar
33. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res. 24(12), 2198–2206 (2007).
Medline CASGoogle Scholar
34. Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomedicine 2(4), 743 (2007).
Medline CASGoogle Scholar
35. Araújo F, Shrestha N, Shahbazi M-A et al. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials 35(33), 9199–9207 (2014).
Medline CASGoogle Scholar
36. Li C, Zhao Y, Cheng J et al. A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota. Adv. Sci. 6(18), 1900610 (2019).
CASGoogle Scholar
37. Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 138(3), 843–853 (2010).
Medline CASGoogle Scholar
38. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64(6), 557–570 (2012).
Medline CASGoogle Scholar
39. Des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Rel. 116(1), 1–27 (2006).
MedlineGoogle Scholar
40. Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs. BioDrugs 19(3), 165–177 (2005).
Medline CASGoogle Scholar
41. Hua S, Marks E, Schneider JJ, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine 11(5), 1117–1132 (2015).
Medline CASGoogle Scholar
42. Xiao B, Merlin D. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin. Drug Deliv. 9(11), 1393–1407 (2012).
Medline CASGoogle Scholar
43. Taipaleenmäki EM, Mouritzen SA, Schattling PS, Zhang Y, Städler B. Mucopenetrating micelles with a PEG corona. Nanoscale 9(46), 18438–18448 (2017).
Medline CASGoogle Scholar
44. Chapman NJ, Brown ML, Phillips SF et al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin. Proc. 67(3), 245–248 (1992).
Medline CASGoogle Scholar
45. Sandborn W, Tremaine W, Leighton JA et al. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment. Pharmacol. Ther. 11(4), 663–671 (1997).
Medline CASGoogle Scholar
46. Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. Nat. Protoc. 1(6), 2876 (2006).
Medline CASGoogle Scholar
47. Mody R, Tramontano A, Paul S. Spontaneous hydrolysis of vasoactive intestinal peptide in neutral aqueous solution. Chem. Biol. Drug Des. 44(5), 441–447 (1994).
CASGoogle Scholar
48. Cui X, Cao D, Qu C, Zhang X, Zheng A. A study of the chemical and biological stability of vasoactive intestinal peptide. Drug Dev. Ind. Pharm. 39(12), 1907–1910 (2013).
Medline CASGoogle Scholar

Vol. 15, No. 25

Supplemental Materials

Metrics

Downloaded 157 times

History

Received 1 July 2020

Accepted 14 August 2020

Published online 25 September 2020

Published in print October 2020

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/nnm-2020-0280

Author contributions

Initial conceptualization was performed by H Onyuksel and PK Dudeja. Evolution of conceptualization was performed by D Jayawardena. Investigations were performed by D Jayawardena, AN Anbazhagan, S Priyamvada and A Kumar. Resources were provided by PK Dudeja, H Onyuksel and S Saksena. Supervision was performed by PK Dudeja and H Onyuksel. D Jayawardena wrote the original draft. Review and editing were performed by all authors.

Acknowledgments

Special thanks to G Guzman, Pathologist at the University of Illinois at Chicago and staff at UIC RRC core imaging facility.

Financial & competing interests disclosure

These studies were supported by the NIDDK grants R01 DK54016, R01 DK92441 (PK Dudeja) and the Department of Veterans Affairs BX 002011 (PK Dudeja) and VA SRCS Award (IK6 BX005242, PK Dudeja), BX 002867 (S Saksena), BX004719 (A Kumar), UIC Dean’s Fellowship (D Jayawardena) and TUBITAK Award (H Onyuksel). This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06 RR15482 from the National Center for Research Resources, NIH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

All animal studies performed were approved by the Animal Care Committee of the University of Illinois at Chicago and Jesse Brown Veterans Affairs Medical Center (IL, USA). The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

PDF download